Bafna Pharmaceuticals Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Bafna Pharmaceuticals Limited Pharmaceutical Export Portfolio Dataset — 6 Products, $2.4M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Bafna Pharmaceuticals Limited — Pharmaceutical Exporter Profile (2026) | 6 Products, $2.4M Trade | TransData Nexus

Bafna Pharmaceuticals Limited

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $2.4M Total Trade · DGFT Verified

Bafna Pharmaceuticals Limited is an Indian pharmaceutical exporter with a total trade value of $2.4M across 6 products in 6 therapeutic categories. Based on 56 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Sitagliptin ($1.3M), Terbinafine ($500.0K), Chlorpheniramine ($300.0K).

Bafna Pharmaceuticals Limited — Export Portfolio & Destination Treemap

Bafna Pharmaceuticals Limited pharmaceutical export portfolio — 6 products across 6 therapeutic categories. Source: Indian Customs (DGFT).

Who is Bafna Pharmaceuticals Limited? — Company Overview & Market Position

Bafna Pharmaceuticals Limited, established in 1981, is a prominent Indian pharmaceutical company specializing in the manufacturing and export of finished pharmaceutical formulations. The company is headquartered in Chennai, Tamil Nadu, India, at Bafna Towers, 299, Thambu Chetty Street, Chennai - 600 001. As of March 2026, Bafna Pharmaceuticals is a subsidiary of SRJR Lifesciences LLP, with a market capitalization of approximately ₹2.35 billion. The company employs around 406 individuals, reflecting its significant presence in the pharmaceutical sector. Bafna Pharmaceuticals is listed on both the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE) under the ticker symbols BAFNAPH and 532989, respectively. The company's website, bafnapharma.com, provides comprehensive information about its products, services, and corporate initiatives.

What Does Bafna Pharmaceuticals Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Sitagliptin$1.3M 2Terbinafine

Product Portfolio — Top 6 by Export Value

Bafna Pharmaceuticals Limited exports 6 pharmaceutical products across 6 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Sitagliptin	Diabetes & Endocrine	$1.3M	26	1.7%	10
2	Terbinafine	Antifungals	$500.0K	10	1.8%	3
3	Chlorpheniramine	Antihistamines & Allergy	$300.0K	6	0.7%	5
4	Mebendazole	Antimalarial & Antiparasitic	$150.0K	3	1.1%	13
5	Terbutaline	Respiratory & OTC	$65.7K	6	1.9%	8
6	Tamoxifen	Advanced Oncology	$48.3K	5	0.3%	12

Bafna Pharmaceuticals Limited exports 6 pharmaceutical products across 6 therapeutic categories with a total export value of $2.4M. The top category is Diabetes & Endocrine (55.0% of portfolio), followed by Antifungals (21.2%), indicating a concentrated portfolio with the top 5 products accounting for 98.0% of total export value.

Bafna Pharmaceuticals Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Bafna Pharmaceuticals operates a state-of-the-art manufacturing facility located in Madhavaram, Chennai. The plant is equipped to produce a diverse range of pharmaceutical formulations, including both Betalactam and Non-Betalactam products. The facility adheres to stringent quality standards, ensuring the production of high-quality medicines for both domestic and international markets.

3Key Leadership

The leadership team at Bafna Pharmaceuticals is spearheaded by Mr. Bafna Mahaveer Chand, who serves as the Chairman and Managing Director. With over three decades of experience in the pharmaceutical industry, Mr. Bafna has been instrumental in the company's growth and diversification. Under his guidance, Bafna Pharmaceuticals has expanded its product portfolio and market reach. Other key executives include Mr. Melagiri Sridhar, the Chief Financial Officer, and Ms. Shanmugam Hemalatha, the Whole-Time Director.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Bafna Pharmaceuticals Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Bafna Pharmaceuticals has established a significant presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained necessary regulatory approvals and certifications to export its pharmaceutical formulations to these regions. In the United States, Bafna Pharmaceuticals has registered its manufacturing facilities with the Food and Drug Administration (FDA), ensuring compliance with stringent quality standards. Similarly, the company holds European Union Good Manufacturing Practice (EU GMP) certifications, allowing it to market its products across EU member states. In the United Kingdom, Bafna Pharmaceuticals has received approvals from the Medicines and Healthcare products Regulatory Agency (MHRA), facilitating the distribution of its products in the UK market. The company's adherence to regulatory requirements in Australia and Japan further underscores its commitment to maintaining high-quality standards in international markets.

2Emerging Markets

Bafna Pharmaceuticals has strategically expanded its footprint into emerging markets, including Africa, Latin America, and Southeast Asia. The company's products are registered and marketed in several countries within these regions, reflecting its commitment to global health. Notably, Bafna Pharmaceuticals has achieved World Health Organization (WHO) prequalification for certain products, enabling access to international procurement programs and enhancing its credibility in these markets. The company's focus on emerging markets aligns with its vision to be a notable player in the global pharmaceutical arena.

Bafna Pharmaceuticals Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Bafna Pharmaceuticals has registered its manufacturing facilities with the U.S. Food and Drug Administration (FDA), ensuring compliance with the agency's stringent quality standards. The company has filed Abbreviated New Drug Applications (ANDAs) for various generic formulations, facilitating market entry in the U.S. Additionally, Bafna Pharmaceuticals has submitted Drug Master Files (DMFs) to the FDA, providing detailed information about the manufacturing processes and quality control measures for its products. The company's facilities have undergone FDA inspections, demonstrating adherence to Good Manufacturing Practices (GMP). Bafna Pharmaceuticals' proactive engagement with the FDA underscores its commitment to maintaining high-quality standards and regulatory compliance in the U.S. market.

2WHO & EU GMP

Bafna Pharmaceuticals has achieved World Health Organization (WHO) prequalification for certain products, enabling access to international procurement programs and enhancing its credibility in global markets. The company's manufacturing facilities are certified for compliance with European Union Good Manufacturing Practice (EU GMP) standards, allowing it to market its products across EU member states. These certifications reflect Bafna Pharmaceuticals' dedication to maintaining high-quality standards and regulatory compliance in international markets.

Bafna Pharmaceuticals Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Bafna Pharmaceuticals operates in a competitive landscape, with several key players in the pharmaceutical industry offering similar products. The company's focus on high-quality formulations and adherence to international regulatory standards positions it favorably in the market. While specific market share data is not publicly available, Bafna Pharmaceuticals' strategic initiatives and product offerings contribute to its competitive standing in the industry.

2Key Differentiators

Bafna Pharmaceuticals' key differentiators include its extensive experience in the pharmaceutical industry, a diverse product portfolio, and a strong commitment to quality and regulatory compliance. The company's manufacturing facilities are accredited by the European Union (EU) Good Manufacturing Practice (GMP), the UK's Medicines and Healthcare products Regulatory Agency (MHRA), and the Australian Therapeutic Goods Administration (TGA), underscoring its adherence to international quality standards. Additionally, Bafna Pharmaceuticals' strategic focus on both regulated and emerging markets enables it to leverage growth opportunities globally.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Bafna Pharmaceuticals Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Bafna Pharmaceuticals has demonstrated a consistent track record in the pharmaceutical industry, with a diverse product portfolio and a strong commitment to quality and regulatory compliance. The company's manufacturing facilities are accredited by international regulatory bodies, including the EU GMP, MHRA, and TGA, indicating a high level of reliability and adherence to global standards. Bafna Pharmaceuticals' proactive approach to quality assurance and regulatory compliance further underscores its reliability as a supplier in the pharmaceutical sector.

2Certifications to Verify

Importers should verify the following certifications when considering Bafna Pharmaceuticals as a supplier:

FDA Facility Registration: Confirm the registration status of Bafna Pharmaceuticals' manufacturing facilities with the U.S. Food and Drug Administration (FDA).

WHO Prequalification: Verify the World Health Organization (WHO) prequalification status of specific products to ensure compliance with international quality standards.

Frequently Asked Questions — Bafna Pharmaceuticals Limited

How many pharmaceutical products does Bafna Pharmaceuticals Limited export from India?

Bafna Pharmaceuticals Limited exports 6 pharmaceutical products across 6 therapeutic categories. The top exports are Sitagliptin ($1.3M), Terbinafine ($500.0K), Chlorpheniramine ($300.0K), Mebendazole ($150.0K), Terbutaline ($65.7K). Total export value is $2.4M.

What is Bafna Pharmaceuticals Limited's total pharmaceutical export value?

Bafna Pharmaceuticals Limited's total pharmaceutical export value is $2.4M, based on 56 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Bafna Pharmaceuticals Limited cover?

Bafna Pharmaceuticals Limited exports across 6 therapeutic categories. The largest are Diabetes & Endocrine (55.0%, 1 products), Antifungals (21.2%, 1 products), Antihistamines & Allergy (12.7%, 1 products).

Get Full Bafna Pharmaceuticals Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.